Quick Answer
RELMADA THERAPEUTICS, INC. reported Total Revenue of $5.1 thousand for fiscal year 2013.
RELMADA THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$57.39M +28.3% |
-$79.98M +19.0% |
-$98.79M +37.1% |
-$157.04M -24.9% |
-$125.75M -111.5% |
-$59.46M -243.3% |
| Diluted EPS | -$1.45 +45.3% |
-$2.65 +19.2% |
-$3.28 +38.1% |
-$5.30 +26.0% |
-$7.16 | — |
| Total Assets | $94.00M +105.2% |
$45.82M -53.0% |
$97.55M -36.2% |
$152.91M -31.5% |
$223.33M +89.0% |
$118.19M +1056.5% |
| Cash and Equivalents | $3.50M -9.3% |
$3.86M -5.7% |
$4.09M -24.2% |
$5.40M -87.9% |
$44.44M +1681.0% |
$2.50M -72.9% |
| Stockholders Equity | $86.51M +143.5% |
$35.52M -58.4% |
$85.36M -39.2% |
$140.44M -32.6% |
$208.26M +97.3% |
$105.58M +1286.8% |
| R&D Expense | $26.88M -41.8% |
$46.18M -15.7% |
$54.81M -51.6% |
$113.32M +25.1% |
$90.62M +151.9% |
$35.97M +412.1% |
| Operating Income | -$59.10M +29.6% |
-$83.89M +19.1% |
-$103.70M +35.7% |
-$161.25M -28.3% |
-$125.70M -106.6% |
-$60.84M -378.0% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 73.33M +143.0% |
30.17M +0.2% |
30.10M +0.0% |
30.10M +8.5% |
27.74M +69.8% |
16.33M +67.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | February 28, 2014 | $682.00 | -70.9% | -63.1% |
| Net Income | September 30, 2025 | -$10.09M | +53.6% | -2.3% |
| Diluted EPS | September 30, 2025 | -$0.30 | +58.3% | +0.0% |
| Total Assets | September 30, 2025 | $14.88M | -73.3% | -29.6% |
| Cash and Equivalents | September 30, 2025 | $1.38M | -6.7% | +2.3% |
| Stockholders Equity | September 30, 2025 | $9.47M | -80.1% | -40.7% |
| R&D Expense | September 30, 2025 | $4.04M | -63.8% | +43.2% |
| Operating Income | September 30, 2025 | -$10.33M | +55.1% | -1.0% |
| Gross Profit | February 28, 2014 | -$3.00 | -100.6% | -101.8% |
| Shares Outstanding | September 30, 2025 | 33.19M | +10.0% | +0.0% |
- RELMADA THERAPEUTICS, INC. reported Total Revenue of $5.1 thousand for fiscal year 2013.
- RELMADA THERAPEUTICS, INC. showed a decrease of -35.4% in Total Revenue compared to the prior fiscal year.
- RELMADA THERAPEUTICS, INC. reported Net Income of -$57.39 million for fiscal year 2025.
- RELMADA THERAPEUTICS, INC. showed an increase of +28.3% in Net Income compared to the prior fiscal year.
- RELMADA THERAPEUTICS, INC. reported Diluted EPS of $1.45 per share (loss) for fiscal year 2025.
- RELMADA THERAPEUTICS, INC. showed an increase of +45.3% in Diluted EPS compared to the prior fiscal year.
- RELMADA THERAPEUTICS, INC. reported Total Assets of $94.00 million for fiscal year 2025.
- RELMADA THERAPEUTICS, INC. showed an increase of +105.2% in Total Assets compared to the prior fiscal year.
- RELMADA THERAPEUTICS, INC. reported Cash and Equivalents of $3.50 million for fiscal year 2025.
- RELMADA THERAPEUTICS, INC. showed a decrease of -9.3% in Cash and Equivalents compared to the prior fiscal year.
- RELMADA THERAPEUTICS, INC. reported Stockholders Equity of $86.51 million for fiscal year 2025.
- RELMADA THERAPEUTICS, INC. showed an increase of +143.5% in Stockholders Equity compared to the prior fiscal year.
- RELMADA THERAPEUTICS, INC. reported R&D Expense of $26.88 million for fiscal year 2025.
- RELMADA THERAPEUTICS, INC. showed a decrease of -41.8% in R&D Expense compared to the prior fiscal year.
- RELMADA THERAPEUTICS, INC. reported Operating Income of -$59.10 million for fiscal year 2025.
- RELMADA THERAPEUTICS, INC. showed an increase of +29.6% in Operating Income compared to the prior fiscal year.
- RELMADA THERAPEUTICS, INC. reported Gross Profit of $1.1 thousand for fiscal year 2013.
- RELMADA THERAPEUTICS, INC. showed a decrease of -49.0% in Gross Profit compared to the prior fiscal year.
- RELMADA THERAPEUTICS, INC. reported Shares Outstanding of 73.33 million shares for fiscal year 2025.
- RELMADA THERAPEUTICS, INC. showed an increase of +143.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: